The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Amputation and Adriamycin in Primary Osteosarcoma
Abstract
Adriamycin has been found effective in metastatic osteogenic sarcoma. To determine its efficacy in osteosarcoma without detectable metastases, 21 patients were given adjuvant adriamycin therapy two weeks (median) after surgical amputation of the primary lesion. Six courses of adriamycin (30 mg per square meter daily for three days, repeated every four to six weeks) were administered. Nineteen of the 21 patients survived from more than one to more than 32 months (median, more than nine months) after operation. Five of the 21 relapsed (two with local and three with pulmonary metastases). At 18 months, 71 per cent of treated patients may be expected to be free of pulmonary metastases as determined by life-table analyses (95 per cent confidence limits, 100 to 43 per cent), in contrast to 30 per cent of the series of 145 patients analyzed by Marcove et al. The data demonstrate an effect of adriamycin in delaying gross metastases from osteosarcoma and are consistent with chemotherapeutic eradication of micrometastases. (N Engl J Med 291:998–1000, 1974)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Adriamycin: A New Anticancer Drug with Significant Clinical Activity
BLUM, R. H., & CARTER, S. K. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-2-249 · Cited by 1,057
Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic Sarcoma
Jaffe, N., Frei, E., Traggis, D., & Bishop, Y. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411072911902 · Cited by 483
McKenna, R. J., Schwinn, C. P., Soong, K. Y., et al. (1966) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-196648010-00001 · Cited by 313
The therapy of osteogenic sarcoma: Current status and thoughts for the future
Friedman, M. A., & Carter, S. K. (1972) · Journal of Surgical Oncology · doi:10.1002/jso.2930040512 · Cited by 275
Recent advances in the chemotherapy of metastatic osteogenic sarcoma
Jaffe, N. (1972) · Cancer · doi:10.1002/1097-0142(197212)30:6<1627::aid-cncr2820300631>3.0.co;2-h · Cited by 273
Cited by
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,204
Ritter, J., & Bielack, S. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq276 · Cited by 1,045
Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention
Pai, V. B., & Nahata, M. C. (2000) · Drug Safety · doi:10.2165/00002018-200022040-00002 · Cited by 729
Biology and Therapeutic Advances for Pediatric Osteosarcoma
Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 671
Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30214-5 · Cited by 551
Metadata
- Authors
- Cortes, E. P., Holland, J. F., Wang, J. J., Sinks, L. F., Blom, J., Senn, H., Bank, A., & Glidewell, O.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1974-11-07
- Volume
- 291
- Issue
- 19
- Pages
- 998-1000
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2327625380
- Cited by
- 317
- References
- 6
- FWCI
- 50.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amputation and Adriamycin in Primary Osteosarcoma. https://app.cochat.ai/papers/10.1056/nejm197411072911903
- The paper
- Cortes, E. P., Holland, J. F., Wang, J. J., Sinks, L. F., Blom, J., Senn, H., Bank, A., & Glidewell, O. (1974). Amputation and Adriamycin in Primary Osteosarcoma. New England Journal of Medicine. https://doi.org/10.1056/nejm197411072911903
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.